Recent Security Class Actions
Mesoblast Limited American Depositary Shares (NASDAQ: MESO)
Company Name:Mesoblast Limited American Depositary Shares
Stock Symbol:NASDAQ: MESO
Class Period Start:12/13/2018
Class Period End (inclusive):10/02/2020
Filing Deadline:12/07/2020
According to the Complaint, Mesoblast Limited develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcelL), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow.
